PMID- 16158422
OWN - NLM
STAT- MEDLINE
DCOM- 20051227
LR  - 20240104
IS  - 1043-3074 (Print)
IS  - 1043-3074 (Linking)
VI  - 27
IP  - 10
DP  - 2005 Oct
TI  - C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck.
PG  - 883-92
AB  - BACKGROUND: Synovial sarcoma is a malignant mesenchymal tumor composed of varying 
      proportions of spindle and epithelial cell components. Because of the histologic 
      and immunohistochemical similarity of synovial sarcoma to epithelial carcinomas, 
      we hypothesized that the human epithelial growth factor receptor 2 (C-erb-B2, 
      also termed HER2/neu) may contribute to the tumor phenotype and provide a new 
      therapeutic target for this soft tissue tumor. METHODS: Three head and neck, one 
      chest wall, and seven extremity synovial sarcomas were evaluated for C-erb-B2 
      (HER2/neu) expression by immunohistochemistry, Western immunoblotting, and 
      fluorescence in situ hybridization (FISH). RESULTS: The head and neck cases 
      demonstrated immunohistochemically strong positive staining, whereas tumors from 
      other anatomic locations showed neither positive nor cytoplasmic restricted 
      staining. Antigen-targeted antibody therapy (trastuzumab) was initiated in two 
      patients. CONCLUSIONS: These results demonstrate that C-erb-B2 (HER2/neu) may 
      play a role in the tumorigenesis of synovial sarcoma; and, therefore, antigrowth 
      factor therapies may provide a previously unrecognized pharmaceutical approach to 
      soft tissue tumors. The data also suggest that although synovial sarcoma of the 
      head and neck and synovial sarcoma of the extremities have similar morphologic 
      features, they may be clinically and mechanistically distinct entities.
CI  - (c) 2005 Wiley Periodicals, Inc.
FAU - Olsen, Randall J
AU  - Olsen RJ
AD  - Department of Pathology and Laboratory Medicine, Baylor College of Medicine, 
      Houston, Texas, USA.
FAU - Lydiatt, William M
AU  - Lydiatt WM
FAU - Koepsell, Scott A
AU  - Koepsell SA
FAU - Lydiatt, Daniel
AU  - Lydiatt D
FAU - Johansson, Sonny L
AU  - Johansson SL
FAU - Naumann, Sabine
AU  - Naumann S
FAU - Bridge, Julia A
AU  - Bridge JA
FAU - Neff, James R
AU  - Neff JR
FAU - Hinrichs, Steven H
AU  - Hinrichs SH
FAU - Tarantolo, Stefano R
AU  - Tarantolo SR
LA  - eng
GR  - P30 CA36727/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/therapeutic use
MH  - Blotting, Western
MH  - Child
MH  - Female
MH  - Genes, erbB-2
MH  - Head and Neck Neoplasms/drug therapy/genetics/*metabolism/pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Receptor, ErbB-2/*metabolism
MH  - Sarcoma, Synovial/drug therapy/genetics/*metabolism/pathology
MH  - Trastuzumab
EDAT- 2005/09/15 09:00
MHDA- 2005/12/28 09:00
CRDT- 2005/09/15 09:00
PHST- 2005/09/15 09:00 [pubmed]
PHST- 2005/12/28 09:00 [medline]
PHST- 2005/09/15 09:00 [entrez]
AID - 10.1002/hed.20267 [doi]
PST - ppublish
SO  - Head Neck. 2005 Oct;27(10):883-92. doi: 10.1002/hed.20267.